Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-09

Inogen Inc (INGN)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,613,804
Kevin R.M. Smith total, FY2025
6th
CEO pay percentile vs peers
35:1
CEO-to-median pay ratio
94.76%
Say-on-pay support, latest vote
Companies that benchmark against INGN
9 companies name INGN as a compensation peer

Each company listed discloses INGN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named INGN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Kevin R.M. Smith$711,077$0$1,874,550$0$0$0$28,177$2,613,804
Chief Executive Officer, President and Director
Michael Bourque450,11201,062,2360162,040034,2271,708,615
Former Executive Vice President, Chief Financial Officer, and Corporate Treasurer
Jennifer Yi Boyer426,6920812,2920128,0080102,3951,469,387
Executive Vice President, Enterprise Enablement and Chief Human Resources Officer
Kevin Smith432,5150874,7730129,755025,9661,463,009
Executive Vice President, General Counsel, Secretary and Business Development
Gregoire Ramade447,3540812,2920158,19901,2261,419,071
Executive Vice President, Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Kevin R.M. Smith$2,613,804$4,159,779$1,796,248−1,545,975
Michael Bourque1,708,6151,887,923−179,308
Jennifer Yi Boyer1,469,387
Kevin Smith1,463,009
Gregoire Ramade1,419,071872,958+546,113

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Yi Boyer Jennifer MEVP Entrprs Enblmnt, Ch HR Off2026-05-29D10,770$7$70,313CommonForm 4 ↗
Elizabeth MoraDirector2026-06-05A28,08100CommonForm 4 ↗
Kevin KingDirector2026-06-05A28,08100CommonForm 4 ↗
Mary Kay LadoneDirector2026-06-05A28,08100CommonForm 4 ↗
Heather RiderDirector2026-06-05A28,08100CommonForm 4 ↗
Mira SahneyDirector2026-06-05A28,08100CommonForm 4 ↗
Vafa JamaliDirector2026-06-05A28,08100CommonForm 4 ↗
Glenn BoehnleinDirector2026-06-05A28,08100CommonForm 4 ↗
Yi Boyer Jennifer MEVP Entrprs Enblmnt, Ch HR Off2026-07-01D10,938772,146CommonForm 4 ↗
Andrew P. RedingEVP, COO2026-07-06D130,00000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Michael BourquePSU2025-02-2851,020102,040$637,240
Michael BourqueRSU2025-02-2851,020424,997
Kevin R.M. SmithRSU2025-02-2842,016349,993
Gregoire RamadeRSU2025-02-2839,015324,995
Jennifer Yi BoyerPSU2025-02-2839,01578,030487,297
Gregoire RamadePSU2025-02-2839,01578,030487,297
Jennifer Yi BoyerRSU2025-02-2839,015324,995
Kevin R.M. SmithPSU2025-02-2842,01684,032524,780
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Michael Bourque$424,997$637,240$060.0%
Kevin R.M. Smith349,993524,780060.0%
Gregoire Ramade324,995487,297060.0%
Jennifer Yi Boyer324,995487,297060.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Kevin R.M. SmithRSU42,016$282,348
Gregoire RamadePSU39,015262,181
Kevin R.M. SmithPSU42,016282,348
Michael BourquePSU37,500252,000
Kevin R.M. SmithRSU36,271243,741
Kevin R.M. SmithRSU28,333190,398
Jennifer Yi BoyerRSU4,68031,450
Michael BourqueRSU50,000336,000
Kevin R.M. SmithRSU90,036605,042
Michael BourquePSU51,020342,854
Gregoire RamadeRSU31,565212,117
Jennifer Yi BoyerPSU21,997147,820
Jennifer Yi BoyerRSU14,66498,542
Kevin R.M. SmithPSU85,000571,200
Jennifer Yi BoyerPSU4,68031,450
Kevin R.M. SmithRSU56,667380,802
Jennifer Yi BoyerPSU39,015262,181
Kevin R.M. SmithPSU42,500285,600
Michael BourqueRSU51,020342,854
Kevin R.M. SmithPSU90,036605,042
Jennifer Yi BoyerRSU39,015262,181
Gregoire RamadeRSU39,015262,181
05

Incentive-plan design — the Compensation Discussion & Analysis

The goals of our executive compensation program are to attract, retain, motivate and reward executive officers who contribute to our success and to incentivize these executives to achieve our short-term and long-term business objectives in order to increase long-term value and increase stockholder returns.

CEO STI target (% of salary)100%
CEO LTI target (% of salary)
Independent consultantAon
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0517,316,134921,78735,30494.76%Passed
20252025-05-1416,712,8861,637,37754,14290.81%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0594.76%a
20252025-05-1490.81%b

a. Approved under the standard stated in the filing — “As a result, abstentions will be counted for purposes of determining the presence or absence of a quorum and will also count as votes against a proposal in cases where approval of the proposal requires (i) the affirmative vote o turned, the shares represented by the proxy will be voted at the Annual Meeting in accordance with the instructions of the stockholder.”.

b. Approved under the standard stated in the filing — “As a result, abstentions will be counted for purposes of determining the presence or absence of a quorum and will also count as votes against a proposal in cases where approval of the proposal requires the affirmative vote of a majority of the shares present virtually in person or represented by proxy and entitled designated as proxy holders by our Board.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)35 : 1
CEO total compensation$2,613,804
Median employee compensation$74,060
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Elizabeth MoraIndependent · Board Chair · Compensation · Nominating/Governance$132,500$179,998$0$0$0$312,498
Mira SahneyIndependent · Compliance · Nominating/Governance50,417255,264000305,681
Glenn BoehnleinIndependent · Audit (Chair) · Compliance70,000179,998000249,998
Mary Kay LadoneIndependent · Audit · Compensation (Chair)70,000179,998000249,998
Kevin KingIndependent · Audit · Compliance (Chair)65,000179,998000244,998
Heather RiderIndependent · Compensation · Nominating/Governance (Chair)62,500179,998000242,498
Thomas A. WestIndependent · Nominating/Governance · Departed during FY4,5830004,583
Vafa JamaliIndependent · Audit · Compliance · Newly elected000000
Kevin R.M. SmithEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)10,000 / 20,000 / 10,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$455,000
Equity awards (grant-date value)$1,155,254
All other compensation$0
Total cost of the board$1,610,254

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Inogen Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Inogen Inc.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Nevro Corporation2023Kevin Thornal$515,625$10,080,173$0$402,750$11,453,548
2TransMedics Group, Inc.2025Waleed Hassanein776,9234,364,0134,360,1471,400,00010,915,533
3Alphatec Holdings, Inc.2025Patrick Miles762,0008,859,6500600,00010,260,507
4AtriCure, Inc.2025Michael Carrel828,4397,203,47801,171,7039,217,620
5Axogen, Inc.2025Michael Dale775,8657,342,8950906,1339,047,454
6STAAR Surgical Company2025Stephen Farrell580,0006,836,000007,522,385
7ZimVie, Inc.2024Vafa Jamali818,4616,367,343007,209,869
8Artivion, Inc.2025J. Patrick Mackin835,1455,006,9900991,3686,883,108
9AngioDynamics, Inc.2025James Clemmer803,0272,628,871808,2071,215,6085,494,285
10Treace Medical Concepts, Inc.2025John Treace755,3534,635,000005,405,190
11Inari Medical, Inc.2023Andrew Hykes700,0002,606,744937,488826,0005,083,365
12OraSure Technologies, Inc.2025Carrie Eglinton Manner721,0003,394,1880173,0404,292,228
13LeMaitre Vascular, Inc.2025George LeMaitre806,3471,050,0001,050,000680,0153,780,990
14Tactile Systems Technology, Inc.2025Sheri Dodd675,0002,019,9780737,4383,466,916
15Inogen Inc2025Kevin R.M. Smith711,0771,874,550002,613,804
16Kewaunee Scientific Corporation2026Thomas Hull III526,190997,9300394,9671,965,495
17Zynex, Inc.2024Thomas Sandgaard700,000112,4580170,625991,810

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Inogen Inc60%RSU 50 · PSU 50NoAon
Alphatec Holdings, Inc.157%PSU 50 · RSU 50NoCompensia, Inc.
AngioDynamics, Inc.150%PSU 50 · RSU 25 · Options 25NoMeridian Compensation Partners, LLC
Artivion, Inc.118.7%PSU 50 · RSU 50NoWillis Towers Watson
AtriCure, Inc.141%PSU 70 · RSU 30NoKorn Ferry
Axogen, Inc.116.79%PSU 50 · RSU 50NoAon
Inari Medical, Inc.118%RSU 75 · Options 25not disclosedFW Cook
Kewaunee Scientific Corporationnot disclosedRSU 50 · PSU 50NoNot named (committee engaged a compensation consultant on a limited basis in 2025 and 2026 but did not disclose the firm name)
LeMaitre Vascular, Inc.144%Options 50 · RSU 25 · PSU 25Nonot disclosed
Nevro Corporation53.7%RSU 50 · PSU 50NoAon
OraSure Technologies, Inc.24.0%RSU 50 · PSU 50Yes — Relative TSR performance vs peer groupPay Governance LLC
STAAR Surgical Company135%RSU 50 · PSU 50NoSemler Brossy
Tactile Systems Technology, Inc.115%PSU 50 · RSU 50NoAon Consulting, Inc.
TransMedics Group, Inc.175%Options 50 · RSU 50not disclosedPearl Meyer
Treace Medical Concepts, Inc.not disclosedRSU 50 · PSU 50NoCompensia, Inc.
ZimVie, Inc.0%RSU 100not disclosedAon
Zynex, Inc.24.4%not disclosednot disclosednot disclosed

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Kevin R.M. SmithDEF 14A2026-04-280001294133-26-000009Section “Compensation Table” · page 23. As printed: 2,613,804. Filing ↗machine: span 1140571–1140580
2Section 01, Michael BourqueDEF 14A2026-04-280001294133-26-000009Section “Compensation Table” · page 23. As printed: 1,708,615. Filing ↗machine: span 1176555–1176564
3Section 01, Jennifer Yi BoyerDEF 14A2026-04-280001294133-26-000009Section “Compensation Table” · page 23. As printed: 1,469,387. Filing ↗machine: span 1255938–1255947
4Section 01, Kevin SmithDEF 14A2026-04-280001294133-26-000009Section “Compensation Table” · page 23. As printed: 1,463,009. Filing ↗machine: span 1203270–1203279
5Section 01, Gregoire RamadeDEF 14A2026-04-280001294133-26-000009Section “Compensation Table” · page 23. As printed: 1,419,071. Filing ↗machine: span 1229653–1229662
6Section 03, Michael Bourque PSUDEF 14A2026-04-280001294133-26-000009Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t19 · r4 · c3 · span 1047316–1047322
7Section 03, Michael Bourque RSUDEF 14A2026-04-280001294133-26-000009Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t19 · r4 · c3 · span 1047316–1047322
8Section 03, Kevin R.M. Smith RSUDEF 14A2026-04-280001294133-26-000009Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t19 · r5 · c3 · span 1053279–1053285
9Section 03, Gregoire Ramade RSUDEF 14A2026-04-280001294133-26-000009Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t19 · r6 · c3 · span 1059240–1059246
10Section 03, Jennifer Yi Boyer PSUDEF 14A2026-04-280001294133-26-000009Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t19 · r7 · c3 · span 1065203–1065209
11Section 03, Gregoire Ramade PSUDEF 14A2026-04-280001294133-26-000009Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t19 · r6 · c3 · span 1059240–1059246
12Section 03, Jennifer Yi Boyer RSUDEF 14A2026-04-280001294133-26-000009Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t19 · r7 · c3 · span 1065203–1065209
13Section 03, Kevin R.M. Smith PSUDEF 14A2026-04-280001294133-26-000009Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t19 · r5 · c3 · span 1053279–1053285
14Section 07, pay ratioDEF 14A2026-04-280001294133-26-000009Section “CEO Pay Ratio”. As printed: 35 : 1. Filing ↗machine: span 1829996–1830003
15Section 08, Elizabeth MoraDEF 14A2026-04-280001294133-26-000009Section “Director Compensation”. As printed: 312,498. Filing ↗machine: t6 · r3 · c15 · span 500927–500934
16Section 08, Mira SahneyDEF 14A2026-04-280001294133-26-000009Section “Director Compensation”. As printed: 305,681. Filing ↗machine: t6 · r8 · c14 · span 531333–531340
17Section 08, Glenn BoehnleinDEF 14A2026-04-280001294133-26-000009Section “Director Compensation”. As printed: 249,998. Filing ↗machine: t6 · r5 · c15 · span 513220–513227
18Section 08, Mary Kay LadoneDEF 14A2026-04-280001294133-26-000009Section “Director Compensation”. As printed: 249,998. Filing ↗machine: t6 · r7 · c15 · span 525508–525515
19Section 08, Kevin KingDEF 14A2026-04-280001294133-26-000009Section “Director Compensation”. As printed: 244,998. Filing ↗machine: t6 · r4 · c15 · span 507071–507078
20Section 08, Heather RiderDEF 14A2026-04-280001294133-26-000009Section “Director Compensation”. As printed: 242,498. Filing ↗machine: t6 · r6 · c15 · span 519367–519374
21Section 08, Thomas A. WestDEF 14A2026-04-280001294133-26-000009Section “Director Compensation”. As printed: 4,583. Filing ↗machine: t6 · r9 · c3 · span 533334–533339
22Section 08, Vafa JamaliDEF 14A2026-04-280001294133-26-000009Section “Director Compensation”. As printed: 0. Filing ↗
23Section 08, Kevin R.M. SmithDEF 14A2026-04-280001294133-26-000009Section “Director Compensation”. As printed: 0. Filing ↗
24Section 02, Yi Boyer Jennifer M 2026-05-29Form 42026-06-020002079957-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Elizabeth Mora 2026-06-05Form 42026-06-090001548935-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Kevin King 2026-06-05Form 42026-06-090001385014-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Mary Kay Ladone 2026-06-05Form 42026-06-090001760737-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Heather Rider 2026-06-05Form 42026-06-090001616363-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Mira Sahney 2026-06-05Form 42026-06-090002054249-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Vafa Jamali 2026-06-05Form 42026-06-090001908985-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Glenn Boehnlein 2026-06-05Form 42026-06-090001670936-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Yi Boyer Jennifer M 2026-07-01Form 42026-07-060002079957-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Andrew P. Reding 2026-07-06Form 42026-07-090001478471-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
34Section 06, 2026 voteForm 8-K2026-06-110001294133-26-000021Item 5.07 · say-on-pay result. As reported: 94.76% (votes for as printed: 17,316,134). Filing ↗
35Section 06, 2025 voteForm 8-K2025-05-190000950170-25-074437Item 5.07 · say-on-pay result. As reported: 90.81% (votes for as printed: 16,712,886). Filing ↗
36Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
37Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
38Section 09b board cost (computed)ComputedcomputedCash 455,000 + equity 1,155,254 + all other 0 = 1,610,254, summed across the director compensation table rows.machine: formula: Σ = 1,610,254
39Nevro Corporation, Section 10b CEO totalDEF 14A2024-04-120000950170-24-044100CEO total compensation as printed in Nevro Corporation's own proxy. As printed: 11,453,548. Filing ↗machine: r2 · c16 · span 631983–631993
40TransMedics Group, Inc., Section 10b CEO totalDEF 14A2026-04-100001193125-26-150357CEO total compensation as printed in TransMedics Group, Inc.'s own proxy. As printed: 10,915,533. Filing ↗machine: r3 · c39 · span 572169–572179
41Alphatec Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-290001193125-26-191867CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. Filing ↗machine: t26 · r2 · c25 · span 858148–858158
42AtriCure, Inc., Section 10b CEO totalDEF 14A2026-04-060001323885-26-000010CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373
43Axogen, Inc., Section 10b CEO totalDEF 14A2026-04-290000805928-26-000057CEO total compensation as printed in Axogen, Inc.'s own proxy. As printed: 9,047,454. Filing ↗machine: r2 · c45 · span 557309–557318
44STAAR Surgical Company, Section 10b CEO totalDEF 14A2026-05-040000718937-26-000015CEO total compensation as printed in STAAR Surgical Company's own proxy. As printed: 7,522,385. Filing ↗machine: r3 · c16 · span 1045477–1045486
45ZimVie, Inc., Section 10b CEO totalDEF 14A2025-03-250001193125-25-061931CEO total compensation as printed in ZimVie, Inc.'s own proxy. As printed: 7,209,869. Filing ↗machine: t241 · r4 · c27 · span 677156–677165
46Artivion, Inc., Section 10b CEO totalDEF 14A2026-04-010001999371-26-007510CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. Filing ↗machine: r3 · c9 · span 741873–741882
47AngioDynamics, Inc., Section 10b CEO totalDEF 14A2025-09-250001628280-25-042704CEO total compensation as printed in AngioDynamics, Inc.'s own proxy. As printed: 5,494,285. Filing ↗machine: r2 · c27 · span 502542–502551
48Treace Medical Concepts, Inc., Section 10b CEO totalDEF 14A2026-04-060001630627-26-000005CEO total compensation as printed in Treace Medical Concepts, Inc.'s own proxy. As printed: 5,405,190. Filing ↗machine: t81 · r4 · c16 · span 1034150–1034159
49Inari Medical, Inc., Section 10b CEO totalDEF 14A2024-03-130001193125-24-066805CEO total compensation as printed in Inari Medical, Inc.'s own proxy. As printed: 5,083,365. Filing ↗machine: r2 · c31 · span 454508–454517
50OraSure Technologies, Inc., Section 10b CEO totalDEF 14A2026-04-300001116463-26-000032CEO total compensation as printed in OraSure Technologies, Inc.'s own proxy. As printed: 4,292,228. Filing ↗machine: t152 · r2 · c21 · span 850376–850385
51LeMaitre Vascular, Inc., Section 10b CEO totalDEF 14A2026-04-140001193125-26-153877CEO total compensation as printed in LeMaitre Vascular, Inc.'s own proxy. As printed: 3,780,990. Filing ↗machine: span 564038–564047
52Tactile Systems Technology, Inc., Section 10b CEO totalDEF 14A2026-03-250001104659-26-034206CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. Filing ↗machine: r3 · c12 · span 865797–865806
53Inogen Inc (subject), Section 10b CEO totalDEF 14A2026-04-280001294133-26-000009CEO total compensation as printed in Inogen Inc's own proxy. As printed: 2,613,804. Filing ↗machine: span 1140571–1140580
54Kewaunee Scientific Corporation, Section 10b CEO totalDEF 14A2026-07-070001140361-26-027713CEO total compensation as printed in Kewaunee Scientific Corporation's own proxy. As printed: 1,965,495. Filing ↗machine: t21 · r2 · c21 · span 177361–177370
55Zynex, Inc., Section 10b CEO totalDEF 14A2025-03-280001558370-25-004019CEO total compensation as printed in Zynex, Inc.'s own proxy. As printed: 991,810. Filing ↗machine: t66 · r5 · c14 · span 277902–277909
56Section 10a, STAAR Surgical Company reciprocityDEF 14A0000718937-26-000015STAAR Surgical Company's most recent proxy was read; its disclosed peer group does not include Inogen Inc. Filing ↗
57Section 10a, OraSure Technologies, Inc. reciprocityDEF 14A0001116463-26-000032OraSure Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Inogen Inc. Filing ↗
58Section 10a, AtriCure, Inc. reciprocityDEF 14A0001323885-26-000010AtriCure, Inc.'s most recent proxy was read; its disclosed peer group does not include Inogen Inc. Filing ↗
59Section 10a, Artivion, Inc. reciprocityDEF 14A0001999371-26-007510Artivion, Inc. names Inogen Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
60Section 10a, Zynex, Inc. reciprocityDEF 14A0001558370-25-004019Zynex, Inc. names Inogen Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
61Section 10a, Axogen, Inc. reciprocityDEF 14A0000805928-26-000057Axogen, Inc.'s most recent proxy was read; its disclosed peer group does not include Inogen Inc. Filing ↗
62Section 10a, Inari Medical, Inc. reciprocityDEF 14A0001193125-24-066805Inari Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include Inogen Inc. Filing ↗
63Section 10a, Nevro Corporation reciprocityDEF 14A0000950170-24-044100Nevro Corporation's most recent proxy was read; its disclosed peer group does not include Inogen Inc. Filing ↗
64Section 10a, ZimVie, Inc. reciprocityDEF 14A0001193125-25-061931ZimVie, Inc. names Inogen Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
65Section 10a, AngioDynamics, Inc. reciprocityDEF 14A0001628280-25-042704AngioDynamics, Inc.'s most recent proxy was read; its disclosed peer group does not include Inogen Inc. Filing ↗
66Section 10a, Alphatec Holdings, Inc. reciprocityDEF 14A0001193125-26-191867Alphatec Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Inogen Inc. Filing ↗
67Section 10a, Tactile Systems Technology, Inc. reciprocityDEF 14A0001104659-26-034206Tactile Systems Technology, Inc. names Inogen Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
68Section 10a, TransMedics Group, Inc. reciprocityDEF 14A0001193125-26-150357TransMedics Group, Inc.'s most recent proxy was read; its disclosed peer group does not include Inogen Inc. Filing ↗
69Section 10a, Treace Medical Concepts, Inc. reciprocityDEF 14A0001630627-26-000005Treace Medical Concepts, Inc.'s most recent proxy was read; its disclosed peer group does not include Inogen Inc. Filing ↗